medigraphic.com

2009, Number 3

<< Back Next >>

Cir Cir 2009; 77 (3)

Recurrence of breast cancer in women residing in northwestern Mexico

Pérez-Michel LMA, González-Lizarraga M, Ornelas-Aguirre JM

Language: Spanish
References: 27
Page: 179-185
PDF size: 101.02 Kb.


ABSTRACT

Background: Recurrence of breast cancer has been defined as the presence of a new local or distant tumor after a year of initial treatment. The aim of this study was to assess the prevalence and characteristics of breast cancer recurrence in women diagnosed with breast cancer in northwestern Mexico. Methods: We designed a cross-sectional study in a cohort of women with breast cancer to determine the prevalence of disease recurrence. We analyzed age, tumor stage, axillary lymph node status, type of tumor, histological grade, estrogen receptor (ER), progesterone receptor (PR) and protein HER2, treatment used and death. Results: We included 397 women, with 23% of recurrence in a follow up to five years. There was a higher frequency of recurrence in those cases where diagnosis was stage III of the disease (48%; OR = 3.54; p = 0.0001). Axillary lymph node metastases (21%; OR = 1.12; p = 0.05) and ER positive (19%; OR = 0.64; p = 0.07) and protein HER2 (28%; OR = 1.53; p = 0.08). Of 121 women who received endocrine therapy, 35 had recurrence (29%; OR = 1.63; p = 0.04) and 15/30 women who received trastuzumab presented recurrence (50%; OR = 3.89; p = 0.01). Death was reported in 77% of cases of disease recurrence (OR = 12.66; p = 0.001). Conclusions: In the late stage of breast cancer, HER2-positive expression in women with ER positive, axillary node involvement and metastases is associated with a higher frequency of recurrence and death.


REFERENCES

  1. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003;5:R30-R36.

  2. Secretaría de Salud. Información para la rendición de cuentas. México: Secretaría de Salud; 2001. p. 38.

  3. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001;91:863-868.

  4. López-Carrillo L, Sánchez-Torres L, López-Cervantes M, Rueda-Neria C. Identificación de lesiones mamarias malignas en México. Salud Publica Mex 2001;43:199-202.

  5. López-Ríos O, Lazcano-Ponce EC, Tovar-Guzmán V, Hernández-Ávila M. La epidemia de cáncer de mama en México. ¿Consecuencia de la transición demográfica? Salud Publica Mex 1997;39:1-7.

  6. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001;27:137-142.

  7. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in earlystage breast cancer. Oncologist 2004;9:606-616.

  8. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.

  9. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors. N Engl J Med 1989;320:479-489.

  10. Gerson R, Serrano A, Villalobos A, Sánchez-Forgach E, Sánchez-Basurto C, Murillo A, et al. Biomarcadores en el pronóstico y respuesta al tratamiento en cáncer mamario. Gac Med Mex 2002;138:15-24.

  11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.

  12. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB Jr. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990;125:107-113.

  13. Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids 2004;68:761-770.

  14. Mohsin SK, Weiss H, Havighurst T, Clark GM, Berardo M, Roanh le D, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-1554.

  15. Rojas-Atencio AE, Valbuena I, Urdaneta K, Soto-Quintana M, Álvarez- Nava F, González L, et al. Relationship of oncogene C-erbB-2 amplification in breast cancer with pathological parameters and disease free survival. Rev Med Chile 2005;133:151-157.

  16. Secretaría de Salud. Norma oficial mexicana (NOM-041-SSA2-2002), para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer de la mama. México: Secretaría de Salud; 2002. Disponible en http://www.fedpatmex.org.mx/Doc_Extras/NOM-041-SSA2-2002%20(NORMA%20DE%20MAMA).pdf

  17. Gerson R, Serrano A. Prognosis in early breast cancer according HER2 and hormone receptors expression. GAMO 2008;7:45-51.

  18. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10:6622-6628.

  19. Haffty BG, Hauser A, Choi DH, Parisot N, Rimm D, King B, et al. Molecular markers for prognosis alter isolated postmastectomy chest wall recurrence. Cancer 2004;100:252-263.

  20. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, et al. Amplification of erb2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9:923-930.

  21. Pedrini JL, Pedrini M, Savaris RF, Machado L, Grudzinski M, Zettler CG. Reassessing tumor markers in local recurrences of breast cancer: a new insight. Med Sci Monit 2004;10:BR462-BR467.

  22. Crawford DJ, Cowan S, Fitch R, Smith DC, Leake RE. Stability of estrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 1987;56:137-140.

  23. Li BD, Bizcos A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994;57:71-77.

  24. Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2001;84:539-544.

  25. Córdoba A, Ederra M, Ariceta I, Gómez ML, Arrechea MA, De Llano P, et al. Modulation of biomarker expression (OR, PR and C-erbB2) in breast cancer following neoadjuvant treatment. An Sist Sanit Navar 2006;29:349-356.

  26. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.

  27. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, et al. Sequential steroid hormone receptor measurement in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 2003;10:91-98.




2020     |     www.medigraphic.com